Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOTIS-9: loncastuximab tesirine plus rituximab in previously untreated unfit or frail DLBCL
2022-501601-12-00Phase 2Completed
- Sponsor
- ADC Therapeutics
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, open-label trial of loncastuximab tesirine and rituximab in diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma and follicular lymphoma (FL) (2 cohorts), sponsored by ADC Therapeutics. Primary endpoints: Complete response rate in Cohort A, Complete response rate in Cohort B and 1 more. Started Feb 2023; status: completed.
02
Drugs
loncastuximab tesirinerituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)large-cell lymphomafollicular lymphoma (FL)
Beyond the preview
Go deeper on 2022-501601-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501601-12-00.